zomedica (nyse american:zom) (tsx-v:zom) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. with a team that includes clinical veterinary professionals, it is zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.
Company profile
Ticker
ZOM
Exchange
Website
CEO
Robert Cohen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zomedica Pharmaceuticals Corp.
SEC CIK
Corporate docs
Subsidiaries
Zomedica Inc. • HMT High Medical Technologies (Japan) Co., Ltd. • NeoPulse GmbH • PVT NeoPulse Acquisition GmbH • Zomedica Biotechnologies, LLC • Structured Monitoring Products, Inc. ...
ZOM stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
4 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Zomedica Provides Corporate NYSE American Listing Update
15 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
29 Feb 24
DEFA14A
Additional proxy soliciting materials
20 Feb 24
DEFA14A
Additional proxy soliciting materials
6 Feb 24
DEFA14A
Additional proxy soliciting materials
31 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEFA14A
Additional proxy soliciting materials
24 Jan 24
DEFA14A
Additional proxy soliciting materials
17 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.78 mm | 21.78 mm | 21.78 mm | 21.78 mm | 21.78 mm | 21.78 mm |
Cash burn (monthly) | 2.06 mm | 1.94 mm | 1.98 mm | 2.11 mm | 1.01 mm | 1.11 mm |
Cash used (since last report) | 13.60 mm | 12.85 mm | 13.11 mm | 13.96 mm | 6.67 mm | 7.35 mm |
Cash remaining | 8.19 mm | 8.94 mm | 8.67 mm | 7.82 mm | 15.11 mm | 14.43 mm |
Runway (months of cash) | 4.0 | 4.6 | 4.4 | 3.7 | 15.0 | 13.0 |
Institutional ownership, Q3 2023
8.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 83 |
Opened positions | 9 |
Closed positions | 13 |
Increased positions | 20 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 13.92 bn |
Total shares | 83.68 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 48.81 mm | $8.16 bn |
BLK Blackrock | 10.39 mm | $1.74 bn |
Geode Capital Management | 9.64 mm | $1.61 bn |
STT State Street | 3.32 mm | $555.05 mm |
ProShare Advisors | 2.99 mm | $499.34 mm |
Brown Brothers Harriman & Co | 2.47 mm | $412.16 mm |
NTRS Northern Trust | 1.79 mm | $298.76 mm |
T. Rowe Price | 485.40 k | $81.70 mm |
BK Bank Of New York Mellon | 436.14 k | $72.88 mm |
Charles Schwab Investment Management | 412.33 k | $68.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Dec 23 | Powers Johnny D | Common Stock, without par value | Buy | Acquire P | No | No | 0.165 | 100,000 | 16.50 k | 1,950,000 |
15 Dec 23 | Powers Johnny D | Common Stock, without par value | Buy | Acquire P | No | No | 0.165 | 100,000 | 16.50 k | 1,950 |
17 Nov 23 | Larry C Heaton Ii | Common Stock, without par value | Buy | Acquire P | No | No | 0.166 | 100,000 | 16.60 k | 200,000 |
17 Nov 23 | Powers Johnny D | Common Stock, without par value | Buy | Acquire P | No | No | 0.166 | 100,000 | 16.60 k | 1,850,000 |
15 Nov 23 | Powers Johnny D | Common Stock, without par value | Buy | Acquire P | No | No | 0.173 | 150,000 | 25.95 k | 1,750,000 |
Press releases
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
9 Apr 24
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
1 Apr 24
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
14 Mar 24
Zomedica Provides NYSE American Listing Update
13 Mar 24
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
12 Mar 24